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The Chemist’s View of Proteins
• Proteins are made from 20 different amino acids, 9 of 
which are essential. 
• Each amino acid has an amino group, an acid group, a 
hydrogen atom, and a side group. 
• It is the side group that makes each amino acid 
unique. 
• The sequence of amino acids in each protein 
determines its unique shape and function.
How Does the Body Use Protein?
• Functions of protein
– Provide structural and mechanical support
– Maintain body tissues
– Functions as enzymes and hormones
– Help maintain acid base balance
– Transport nutrients
– Assist the immune system
– Serve as a source of energy when necessary
Proteins in the Body
• The synthesis of protein is determined by genetic 
information. 
• Protein is constantly being broken down and synthesized in 
the body. 
• Researchers measure nitrogen balance to study synthesis, 
degradation and excretion of protein. 
• Protein has many important functions in the body. 
• Protein can be used for energy if needed; its excesses are 
stored as fat. 
• The study of proteins is called proteomics.
Digestion of Protein
• The goal of protein digestion is the hydrolysis of all 
peptide bonds to produce free amino acids. 
• No chemical digestion of protein occurs in the 
mouth.
(peptide bonds are amide bonds)
© 2008 Thomson - Wadsworth
HCl in the stomach (pH 1–2) 
denatures dietary protein.
Gastric secretions also include 
pepsinogen, which activated by 
acid produces the enzyme pepsin.
Pepsin is stable and active at pH 1–
2, it hydrolyzes some of the peptide 
bonds in the denatured proteins, 
which are broken down into 
smaller polypeptides.
Digestion of Proteins (contd.)
• Next, the polypeptides enter the small intestine, where the pH 
is about 7–8. 
• Proteases such as (trypsin, chymotrypsin, and 
carboxypeptidase) take over further hydrolysis of peptide 
bonds in the partially digested proteins.
• The combined action of the pancreatic proteases in the small 
intestine and other proteases in the cells of the intestinal 
lining frees the amino acids from dietary proteins. 
• After active transport across cell membranes lining the 
intestine, the amino acids are absorbed directly into the 
bloodstream.
Digestion of Proteins (contd.)
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Digestion of Proteins
Amino acid pool: The entire collection of free amino acids 
in the body
Each of the 20 amino acids is degraded via its 
own unique pathway.
But the general scheme for amino acid catabolism is the 
same for each one:
-Removal of the amino group
-Use of nitrogen in synthesis of new nitrogen compounds
-Passage of nitrogen into the urea cycle
-Incorporation of the carbon atoms into compounds that can 
enter the citric acid cycle 
Our bodies do not store nitrogen-containing compounds 
and ammonia is toxic to cells. 
Fates of carbon 
skeleton of 
amino acids
Ketogenic/Glucogenic Amino Acids
Amino acids converted to acetoacetyl
-SCoA Or acetyl-SCoA are called
ketogenic amino acids.
Amino acids that proceed by way of 
oxaloacetate pathway 
are known as glucogenic amino acids
If the amino acids are not being used to make new proteins,
their carbon skeletons can be used to generate energy.
So….
Fate of Amino Nitrogen’s
Amino nitrogen are either incorporated into urea and excreted
or be used in the synthesis of new nitrogen-containing 
compounds such as:
-Nitric oxide 
-Hormones
-Neurotransmitters
-Nicotinamide (in NAD+ and NADP+ )
-Heme (in red blood cells)
-Purine and pyrimidine bases (for nucleic acids)
How Much Protein Do You 
Need?
• Healthy, nonpregnant adults
– Should consume enough to replace what is used 
every day
– The goal is nitrogen balance
• Pregnant woman, people recovering from 
surgery or injury, and growing children
– Should consume enough to build new tissue
Nitrogen Balance and Imbalance
Figure 6.12
Eating Too Little Protein
• Protein-energy malnutrition (PEM)
– Protein is used for energy rather than its other 
functions in the body
– Other important nutrients are in short supply
– More prevalent in infants and children
• 17,000 children die each day as a result
Too Little Protein
• Without adequate protein
– Cells lining the GI tract are not sufficiently 
replaced as they slough off
– Digestive function is inhibited
– Absorption of food is reduced
– Intestinal bacteria gets into the blood and 
causes septicemia
– Immune system is compromised due to 
malnutrition and cannot fight infection
Types of PEM: Kwashiorkor
 Severe protein deficiency
– Generally result of a diet high in 
grains and deficient in protein
 Symptoms range from
– Edema in legs, feet, and stomach
– Muscle tone and strength diminish
– Hair is brittle and easy to pull out
– Appear pale, sad, and apathetic
– Prone to infection, rapid heart rate, 
excess fluid in lungs, pneumonia, 
septicemia, and water and electrolyte 
imbalances
Figure 6.16
Types of PEM: Marasmus
 Results from a severe deficiency in 
kilocalories
– Frail, emaciated appearance
– Weakened and appear apathetic
– Many cannot stand without support
– Look old
– Hair is thin, dry, and lacks sheen
– Body temperature and blood pressure 
are low
– Prone to dehydration,infections, 
and unnecessary blood clotting
Types of PEM: Marasmic Kwashiorkor
• Chronic deficiency in 
kilocalories and protein
– Have edema in legs and arms
– Have a “skin and bones”
appearance
– With treatment the edema 
subsides and appearance becomes 
more like someone with 
marasmus
Health Effects and Recommended Intakes of 
Protein
• Health Effects of Protein
– Heart Disease
• Foods high in animal protein also tend to be high in saturated 
fat.
• Homocysteine levels increase cardiac risks.
– Cancer
• A high intake of animal protein is associated with some 
cancers.
• Is the problem high protein intake or high fat intake?
– Adult Bone Loss (Osteoporosis)
• High protein intake associated with increased calcium 
excretion.
• Inadequate protein intake affects bone health also.
Amino acid oxidation and the 
production of urea
Waste or reuse
Oxidation
Ammonia has to be eliminated
• Ammonia originates in the catabolism of amino 
acids that are primarily produced by the 
degradation of proteins – dietary as well as 
existing within the cell:
digestive enzymes
muscle proteins
hemoglobin
intracellular proteins (damaged, unnecessary)
Ammonia has to be eliminated
• Ammonia is toxic, especially for the CNS, because 
it reacts with -ketoglutarate, thus making it 
limiting for the TCA cycle  decrease in the ATP 
level
• Liver damage or metabolic disorders associated 
with elevated ammonia can lead to tremor, slurred 
speech, blurred vision, coma, and death
• Normal conc. of ammonia in blood: 30-60 µM
Overview of amino acid catabolism in mammals
2 CHOICES
1. Reuse
2. Urea cycle 
Fumarate 
Oxaloacetate 
Nitrogen removal from amino acids
Transamination
Oxidative
deamination
Urea cycle
Aminotransferase
PLP
Nitrogen removal from amino acids
Step 1: Remove amino group
Step 2: Take amino group to liver for 
nitrogen excretion
Step 3: Entry into mitochondria
Step 4: Prepare nitrogen to enter urea cycle
Step 5: Urea cycle
Excretory forms of nitrogen
a) Excess NH4
+ is excreted as ammonia (microbes, aquatic 
vertebrates or larvae of amphibia),
b) Urea (many terrestrial vertebrates)
c) or uric acid (birds and terrestrial reptiles)
Step 1. Remove amino group
• Transfer of the amino group of an amino acid to an -keto 
acid  the original AA is converted to the corresponding 
-keto acid and vice versa: 
• Transamination is catalyzed by transaminases 
(aminotransferases) that require participation of 
pyridoxalphosphate:
amino acid
pyridoxalphosphate Schiff base
Step 2: Take amino group to liver for 
nitrogen excretion
Glutamate
dehydrogenase
The glutamate dehydrogenase of mammalian 
liver has the unusual capacity to use either 
NAD+ or NADP+ as cofactor
Glutamate releases its amino group 
as ammonia in the liver.
The amino groups from many of the 
-amino acids are collected in the 
liver in the form of the amino group 
of L-glutamate molecules.
1. Glutamate
transferres one amino group WITHIN cells:
Aminotransferase → makes glutamate from -ketogluta-rate
Glutamate dehydrogenase → opposite 
2. Glutamine
transferres two amino group BETWEEN cells → releases its 
amino group in the liver
3. Alanine
transferres amino group from tissue (muscle) into the   liver
Nitrogen carriers
Move within cells
SynthAtase = ATP
In liver
Move between cells
Glucose-alanine cycle
Ala is the carrier of ammonia and of 
the carbon skeleton of pyruvate from 
muscle to liver.
The ammonia is excreted and the 
pyruvate is used to produce glucose, 
which is returned to the muscle.
Alanine plays a special role in transporting 
amino groups to liver.
Sources of ammonia for the urea cycle:
• Oxidative deamination of Glu, accumulated in the liver by the action of 
transaminases and glutaminase
• Glutaminase reaction releases NH3 that enters the urea cycle in the liver (in the 
kidney, it is excreted into the urine)
• Catabolism of Ser, Thr, and His (nonoxidative deamination) also releases 
ammonia:
Serine - threonine dehydratase
Serine →→ pyruvate + NH4
+
Threonine →→ -ketobutyrate + NH4
+
• Bacteria in the gut also produce ammonia.
Review:
• Nitrogen carriers  glutamate, glutamine, alanine
• 2 enzymes outside liver, 2 enzymes inside liver:
– Aminotransferase (PLP) → -ketoglutarate → 
glutamate
– Glutamate dehydrogenase (no PLP) → glutamate → -
ketoglutarate (in liver)
– Glutamine synthase → glutamate → glutamine
– Glutaminase → glutamine → glutamate (in liver)
Step 3: entry of nitrogen to mitochondria
Step 4: prepare nitrogen to enter urea cycle
Regulation 
Step 5: Urea cycle
aspartate
Ornithine 
transcarbamoylase
Argininosuccinate 
synthase
Argininosuccinate 
lyase
Arginase 1
OOA
Oxaloacetate → aspartate
Urea cycle – review
(Sequence of reactions)
• Carbamoyl phosphate formation in mitochondria is a 
prerequisite for the urea cycle
– (Carbamoyl phosphate synthetase)
• Citrulline formation from carbamoyl phosphate and 
ornithine 
– (Ornithine transcarbamoylase)
• Aspartate provides the additional nitrogen to form 
argininosuccinate in cytosol
– (Argininosuccinate synthase)
• Arginine and fumarate formation
– (Argininosuccinate lyase)
• Hydrolysis of arginine to urea and ornithine
– (Arginase)
Deficiencies of urea cycle 
enzymes
Ammonia toxicity
Ammonia encephalopathy 
• Increased concentration of ammonia in the blood and other 
biological fluids → ammonia difuses into cells, across 
blood/brain barrier → increased synthesis of glutamate 
from -ketoglutarate, increased synthesis of glutamine
 -ketoglutarate is depleted from CNS →  inhibition of 
TCA cycle and production of ATP
• Neurotransmitters – glutamate (excitatory neurotr.) and 
GABA (inhibitory neurotr.), may contribute to the CNS 
effects – bizarre behaviour 
Deficiencies of urea cycle enzymes
• Infant born with total deficiency of one or more enzymes survive at 
least several days.
• Many enzymes deficiencies are partial → enzymes have altered Km
values.
• Case are known of deficiencies of each enzymes.
• Interruption of the cycle at each point affected nitrogen metabolism 
differently - some of the intermediates can diffuse from hepatocytes → 
accumulate in the blood → pass into the urine.
• If symptoms are not detected early enough → severe mental 
retardation → brain damage is irreversible.
N-acetylglutamate synthase deficiency:
• Deficiency or genetic mutation of enzyme (autosomal recessive) → urea 
cycle failure.
• A severe neonatal disorder with fatal consequences, if not detected 
immediately upon birth. 
• Hyperammonemia and general hyperaminoacidemia in a newborn (liver 
contain no detectable ability to synthesize N-acetylglutamate).
• Early symptoms include lethargy, vomiting, and deep coma. 
• Treatment with structural analog N-carbamoyl-L-glutamate – activates 
CPS-I, mitigates the intensity of the disorder, 
Carbamoyl phosphate synthetase (CPS I) deficiency:
• autosomal recessive metabolic disorder, associated with mental retardation 
and developmental delay.
• Hyperammonemia has been observed in 0 – 50% of normal level of CPS-I 
synthesis in the liver.
• Treatment with benzoate and phenylacetate → hippurate and Phe-Ac-Gln
are excreted in the urine:
Ornithine transcarbamoylase (OTC) deficiency
• The most common urea cycle disorder, resulting in a mutated and 
ineffective form of the enzyme.
• X-linked recessive disorder caused by a number of different mutations in 
the OTC gene – males are generally more seriously affected than females 
(males are asymptomatic as heterozygotes).
• Complications with OTC may include mental retardation and 
developmental delay.
Argininosuccinate synthase deficiency – citrullinemia
(citrullinuria)
• autosomal recessive metabolic disorder, inability to condense citrulline with 
aspartate.
• Accumulation of citrulline in blood and excretion in the urine.
• Type I citrullinemia - usually becomes evident in the first few days of life. 
• Type II citrullinemia - the signs and symptoms usually appear during 
adulthood and mainly affect the nervous system.
• Therapy – specific supplementation with arginine
Argininosuccinate lyase deficiency (argininosuccinate aciduria)
• Rare autosomal recessive disorder, argininosuccinate is excreted in large amount in 
urine.
• The severity of symptoms varies greatly, it is hard to evaluate the effect of therapy 
– useful is dietary restriction of nitrogen.
Arginase deficiency (argininemia)
• Rare autosomal recessive disorder that cause many abnormalities in development 
and function of CNS.
• Accumulation and excretion of arginine in urine and arginine precursors and 
products of arginine metabolism.
• Therapy – low nitrogen compounds diet (including essential amino acids
Which of amino acid carries the 
amino group from muscles to the 
liver?
Glucose-alanine cycle
Ala is the carrier of ammonia and of 
the carbon skeleton of pyruvate from 
muscle to liver.
The ammonia is excreted and the 
pyruvate is used to produce glucose, 
which is returned to the muscle.
Alanine plays a special role in transporting 
amino groups to liver.
According to D. L. Nelson, M. M. Cox :LEHNINGER. PRINCIPLES OF BIOCHEMISTRY Fifth edition 
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Degradation of Aromatic Amino Acids
Acetoacetate, fumarate, and pyruvate — are common intermediates. 
Molecular oxygen is used to break an aromatic ring.
homogentisate 
oxidase
+O2tetrahydro-
biopterin
PA hydro-xylase
Phenylketonuria is caused by an absence or deficiency
of phenylalanine hydroxylase or of its 
tetrahydrobiopterin cofactor. 
Phenylalanine accumulates in all body fluids and converts 
to phenylpyruvate. 
Defect in 
myelination of nerves
The brain weight is 
below normal.
Mental and physical
retardations.
The life expectancy
is drastically 
shortened. 
Diagnostic criteria:
 phenylalanine level in 
the blood 
 FeCl3 test
 DNA probes 
(prenatal)
Overall the reaction is considered a mixed function 
oxidation, because one O atom of O2 is reduced to water 
while the other is incorporated into the amino acid product.
 
CH2 CH COO

NH3
+
CH2 CH COO

NH3
+
HO
phenylalanine 
tyrosine 
O2 + tetrahydrobiopterin 
H2O + dihydrobiopterin 
Phenylalanine 
Hydroxylase 
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PHENYLALANINE
O2, tetrahydrobiopterin, and the iron atom in the ferrous 
(Fe++) oxidation state participate in the hydroxylation. 
O2 is thought to react initially with the tetrahydrobiopterin 
to form a peroxy intermediate.
 
His 
His 
Glu 
7,8-dihydrobiopterin 
Phenylalanine 
Hydroxylase PDB 1DMW 
Phenylalanine Hydroxylase
includes a non-heme iron
atom at its active site.  
X-ray crystallography has 
shown the following are 
ligands to the iron atom: 
His N, Glu O & water O. 
(Fe shown in spacefill & 
ligands in ball & stick).
deamination via transaminase) accumulate in blood & urine.
Mental retardation results unless treatment begins 
immediately after birth. Treatment consists of limiting 
phenylalanine intake to levels barely adequate to support 
growth. Tyrosine, an essential nutrient for individuals with 
phenylketonuria, must be supplied in the diet. 
                                   Transaminase
               Phenylalanine          Phenylpyruvate
                                                  (Phenylketone)
  Phenylalanine     Deficient in
    Hydroxylase      Phenylketonuria
                     Tyrosine                  Melanins
           Multiple
        Reactions
         Fumarate + Acetoacetate
Genetic deficiency 
of Phenylalanine 
Hydroxylase leads 
to the disease 
phenylketonuria.
Phenylalanine & 
phenylpyruvate 
(the product of 
phenylalanine
Tyrosine is a precursor for synthesis of melanins and of 
epinephrine and norepinephrine. 
High [phenylalanine] inhibits Tyrosine Hydroxylase, on 
the pathway for synthesis of the pigment melanin from 
tyrosine. Individuals with phenylketonuria have light 
skin & hair color. 
                                   Transaminase
               Phenylalanine          Phenylpyruvate
                                                  (Phenylketone)
  Phenylalanine     Deficient in
    Hydroxylase      Phenylketonuria
                     Tyrosine                  Melanins
           Multiple
        Reactions
         Fumarate + Acetoacetate

INBORN ERRORS OF AMINO ACIDS METABOLISM
Alcaptonuria - inherited disorder of the 
tyrosine metabolism caused by the 
absence of homogentisate oxidase. 
 homogentisic acid is accumulated and 
excreted in the urine
 turns a black color upon exposure to air
 In children:
 urine in diaper may 
darken
 In adults:
 darkening of the ear
 dark spots on the on the 
sclera and cornea
 arthritis
Urine turns a black color upon exposure to air
Alcaptonuria
Aortic valve stenosis in alcaptonuria
Accumulation of oxidized homogentisic acid 
pigment in connective tissue (ochronosis)
Arthritis of the spine is a complication 
of alkaptonuria ochronosis
Albinism –
genetically 
determined lack or 
deficit of enzyme 
tyrosinase
Tyrosinase in
melanocytes 
oxidases tyrosine 
to DOPA and 
DOPA-chinone
tyrosinase
Phenylalanine
Tyrosine Tyroxine
Melanin
DOPA
Dopamine
Norepinephrine
Epinephrine
Symptoms of albinism:
• inhibition of production
or lack of melanin in skin,
hair, eyes
• increased sensitivity to
sunlight
• increased risk of skin
cancer development
• sun burns
• photophobia
• decrease of vision
acuity
Biosynthesis of Catecholamines

Important fetures of catecholamine biosynthesis, 
uptake and signaling
1. Biosynthesis
2. Release
3. Uptake (transporter)
4. Receptor-mediated 
signaling
5. Catabolism
Tyrosine L-Dopa Dopamine
Norepinephrine
Epinephrine
Catecholamines
Normetanephrine
Metaneprine
PNMT
DBH
COMT
COMT
Metabolites
Homovanillic acid
(HVA)
MAO, COMT
Vanillymandelic Acid
(VMA)
MAO
MAOTumor Secretion:
• Large Pheo: more metabolites
(metabolized within tumor before release)
• Small Pheo: more catecholamines
• Sporadic Pheo: Norepi > Epi
• Familial Pheo: Epi > Norepi
• Paraganglioma: Norepi
• Cheodectoma, glomus jugulare: Norepi
• Gangioneuroma: Norepi 
• Malignant Pheo: Dopamine, HVA 
• Neuroblastoma: Dopamine, HVA
TH
Adrenergic Receptors
• Alpha-Adrenergic Receptors
• 1: vasoconstriction, intestinal relaxation, uterine
contraction, pupillary dilation
• 2:  presynaptic NE (clonidine), platelet aggregation,
vasoconstriction,  insulin secretion
• Beta-Adrenergic Receptors
• 1:  HR/contractility,  lipolysis,  renin secretion 
• 2: vasodilation, bronchodilation,  glycogenolysis
• 3:  lipolysis,  brown fat thermogenesis
Catecholamine Producing Tumors
Neural Crest
Sympathoadrenal Progenitor Cell
(Neuroblasts)
Chromaffin Cell Sympathetic Ganglion Cell
Intra-adrenal     Extra-adrenal
Pheochromocytoma
Ganglioneuroma
Neuroblastoma
• Pheochromocytoma
• Paraganglioma (extra-adrenal pheo)
• Originate in extra-adrenal sympathetic chain/chromaffin tissue
• Ganglioneuroma
• Behave like paraganglioma biochemically
• Neuroblastoma
• Common malignancy in children, adrenal
• Catecholamine humoral effects usually minor
• Rapid growth & widespread metastasis
Catecholamine Producing Tumors
Pheochromocytomas
• Catecholamine secreting 
tumor of chromaffin 
tissues
• Pheochromocytomas can 
be found anywhere 
chromaffin tissues exist
Signs and Symptoms
• HTN
• Tachycardia
• Diaphoresis
• Headaches
• Weight loss
• Palpitations
• Orthostatic hypotension
Pheochromocytoma Triad
• Diaphoresis
• Tachycardia
• Headaches
• <0.5% of hypertensive 
patients are diagnosed 
with pheochromocytoma
• Usually in patients 30-50 
yrs.  But can occur at any 
age.  
• Male=Female
Diagnosis
• Blood catecholamine levels 
• Pheochromocytomas are found on CT and 
MRI.
• 24hr urine collection
• free norepinephrine
• catecholamines have a short half life.
• False positives: same as for 24h urine testing, 
also with diuretics, smoking
• Plasma total catechols > 11.8 nM (2000 pg/mL)
• SEN 85%  SPEC 80%
• Drawn with patient fasting, supine, with an 
indwelling catheter in place > 30 min
•
Diagnosis
• Vanillymandelic acid (VMA).
• Final common product of both catecholamine 
metabolic pathways
• Often used as an initial test specificity and 
sensitivity.  ↓ cost
Plasma Metanephrines
• Not postural dependent: can draw normally
• Secreted continuously by pheo
• SEN 99%  SPEC 89%
• False Positive: acetaminophen
Biochemical Tests: Summary
SEN SPEC
Ucatechols 83% 88%
Utotal metanephrines 76% 94%
Ucatechols+metaneph 90% 98%
UVMA 63% 94%
Plasma catecholamines 85% 80%
Plasma metanephrines 99% 89%
Localization: Imaging
• CT abdomen
• Adrenal pheo SEN 93-100%
• Extra-adrenal pheo SEN 90%
• MRI
• > SEN than CT for extra-adrenal pheo
Classification of Dopamine receptors
structure of dopamine D2 receptor
Dynamics of catecholamine receptors 
(up-regulation and down-regulation)
catecholamine receptor
agonist
antagonist
The Conversion of Branched-Chain Amino Acids
The degradative pathways of valine and isoleucine resemble 
that of leucine. 
Isoleucine yields acetyl CoA and propionyl CoA
Valine yields CO2 and propionyl CoA.
branched-chain 
dehydrogenase
Dietary Protein
Catabolized Tissue Protein
Leucine Isoleucine Valine
-ketoisocaproic -keto-3-methylvaleric -ketoisoval
acetyl-CoA + acetyl-CoA + Propionyl-CoA
Acetoacetate Propionyl-CoA
Succinyl-CoA Succinyl-CoA
branched-chain -ketoacid dehydrogenase 
complex
Maple syrup urine disease - the disorder of the 
oxidative decarboxylation of -ketoacids derived 
from valine, isoleucine, and leucine caused by the 
missing or defect of branched-chain dehydrogenase. 
The levels of branched-chain amino 
acids and corresponding -ketoacids
are markedly elevated in both blood 
and urine. 
The urine has the odor of maple syrup
The early symptoms:
 lethargy 
 ketoacidosis
 unrecognized disease leads to 
seizures, coma, and death
 mental and physical retardation  
 H3C S C
H2
C
H2
H
C COO

NH3+CH2
+
O
OHOH
HH
HH
Adenine
HS C
H2
C
H2
H
C COO

NH3+
S C
H2
C
H2
H
C COO
NH3+CH2
O
OHOH
HH
HH
Adenine
homocysteine 
S-adenosyl-
methionine  
(SAM) 
S-adenosyl-
homocysteine 
adenosine   H2O 
acceptor 
methylated acceptor 
SAM is a methyl group 
donor in synthetic reactions. 
The resulting                         
S-adenosylhomocysteine is 
hydrolyzed to homocysteine.
Homocysteine may be 
catabolized via a  complex 
pathway to cysteine & 
succinyl-CoA. 
Methionine Degradation
S-adenosylmethionine (SAM) - a common methyl donor in 
the cell 
Homocysteine (< 15 μmol/L)
Hyperhomocysteinemia can results in:
•Vascular diseases, endothelial 
dysfunction, atherosclerosis, 
thrombophilia
•Skeletal anomalies
•retardation of mental development
•Alzheimer's disease
•Kidneys insufficiency
•Colorectal cancer
Homocysteine
HOMOCYSTINURIA AND HEART DISEASE
Homocystinuria: homocystinmethyl transferase  deficiency
some patients with arteriosclerosis have elevated homocysteine
low plasma B vitamins and low dietary intake show increased risk 
for heart disease
folate/B12 deficiency common in high risk populations (elderly, 
smokers)
B vitamins decrease plasma homocysteine ,  homocysteine may 
oxidatively damage lipoproteins and endothelia of  vessel walls
Cystinuria : cystin-lysinuria , membrane system transport deficiency
Cystinosis : lysosomal function deficiency
Homocystinuria :cystathionine synthase deficiency
Cystathioninuria : cystathionine lyase defieciency + B6 deficiency
Purine 
and
Pyrimidine 
Metabolism 
DNA and RNA Degradation
Source of each atom in the purine ring
 
 
 
N 
N 
N 
N 
9 
1 
8 
7 6 
5 
4 
3 
2 
Glycine 
N
10
-Formyl-FH4 
N
10
-Formyl-FH4 
Aspartate 
   (amine) 
CO2 
Glutamine (amide) 
Major Bases
Ribose-5-phosphate
5-Phosphoribosyl-1-pyrophosphate (PRPP)
⊖
⊕
⊖
⊖
5-Phosphoribosylamine
IMP
Adenylosuccinate XMP
AMP GMP
⊖⊖
Summary and Regulation
“Salvage Pathway” for Purines
(~90%)
Lesch-Nyhan Syndrome
Degradation of Purines
URATE, HYPERURICEMIA & 
GOUT
• Urate: end product of purine metabolism
• Hyperuricemia: serum urate > urate solubility (> 6.8 
mg/dl)
• Gout: deposition of monosodium urate crystals in tissues
• Hyperuricemia caused by
Overproduction
Underexcretion
GOUT: A Chronic Disease of 4 
stages
• Asymptomatic hyperuricemia
• Acute Flares of crystallization
• Intervals between flares
• Advanced Gout & Complications
ACUTE GOUTY FLARES
• Abrupt onset of severe joint inflammation, 
often nocturnal;
Warmth, swelling, erythema, & pain;
Possibly fever
• 90% 1st attacks are monoarticular
SITES OF ACUTE FLARES
• 90% of gout patients 
eventually have 
podagra : 1st MTP 
joint
TOPHI
• Solid urate deposits in 
tissues
TOPHI RISK FACTORS
• Long duration of hyperuricemia
• Higher serum urate
• Long periods of active, untreated gout
GOUT RISK FACTORS
• Male
• Postmenopausal 
female
• Older
• Hypertension
• Pharmaceuticals:
Diuretics, ASA, 
cyclosporine
GOUT RISK FACTORS
• Transplant
• Alcohol intake
Highest with beer
High BMI (obesity)
• Diet high in meat & seafood
SYNOVIAL FLUID
URICOSURIC AGENTS
• Probenecid, (Losartan & fenofibrate for 
mild disease)
• Increased secretion of urate into urine
• Reverses most common physiologic 
abnormality in gout ( 90% pt.s are 
underexcretors)
Acute Flare Med Choices
• NSAIDS
• Colchicine
• Corticosteroids
XANTHINE OXIDASE 
INHIBITOR
• Allopurinol :
• Blocks conversion of hypoxanthine to uric 
acid
• Effective in overproducers
• May be effective in underexcretors
• Can work in pt.s with renal insufficiency
Allopurinol
Inhibits xanthine oxidase
X
X
Inhibition of Purine Biosynthesis by the 
Antitumor Agent, 6-Mercaptopurine
1) 6-Mercaptopurine is converted to a nucleotide.   
2) The nucleotide inhibits purine biosynthesis at 
steps 2, 12,, and 13.      
What is LNS? 
• LNS is a genetic disorder first discovered in 1964 
by Michael Lesch and William Nyhan.
• It is a recessive disease that is linked to the X 
chromosome
• It is caused by a deficiency of the enzyme 
hypoxanthine-guanine phosphoribosyltransferase 
(HPRT)
HPRT’s role in the body
• Hypoxanthine-guanine phosphoribosyltransferase is an 
enzyme that plays a key role in the recycling of the purine 
bases, hypoxanthine, and guanine into purine nucleotide 
pools
• Without HPRT the purine bases are broken down and 
excreted as uric acid
• Since these purine bases cannot be reused, the production of 
purine bases is increased 
• Both of these together cause a significant overproduction of 
uric acid
Symptoms of LNS
• Urate crystal formations, 
which look like orange 
sand, are deposited in 
diapers of the babies
• Kidney stones
• Blood in the urine
• Dysphagia (difficulty 
swallowing)
• Swelling of the joints
• Vomiting
• Athetosis (uncontrolled 
spastic muscle movements 
of the arms and legs)
• Chorea (purposeless 
repetitive movements)
• Moderate mental 
retardation
• Irritability
All of the following are a result of an overproduction of 
Uric Acid
Statistics
• Frequency:
-Reported prevalence is 1 per 380,000 
• Mortality: 
-Few patients live beyond 40 years. 
-The drug allopurinol  is used to control hyperuricernia. 
Most patients experience progressive dysphagia 
(difficulty swallowing) and die after pneumonia . 
-Also common is sudden unexpected death, even to 
patients in stable medical condition.
• Race: 
-LNS effects most races with equal frequency. 
Heme 
Porphyrines
Overview of Porphyrias
• Metabolic disorders involving defects in 
heme biosynthesis
• May be inherited or acquired
• Most inherited forms are autosomal 
dominant, some are autosomal recessive
  
N
Pyrrole
Structure


Porphyrias
Overview of Porphyrias:
• Classified into acute and non-acute
• Acute:
– Acute intermittent porphyria
– Variegate porphyria
– Hereditary coproporphyria
• Non-acute:
– Porphyria cutanea tarda
– Erythropoietic protoporphyria
– Congenital Porphyria
Porphyrinurias:  lead, alcohol, iron-deficiency anemia, liver 
disease


Erythropoietic Protoporphyria
Porphyria Cutanea Tarda
Wednesday, June 29, 
2016
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Hemoglobin 
Catabolism
Heme and  bilirubin 
 Heme four pyrrols rings connected together to form 
(porphyrin).
 Bilirubin consists of open chain of four pyrrols-like rings
Definition of bilirubin 
 Bilirubin is the water insoluble breakdown product of normal 
heme catabolism 
 It’s a yellow pigment present in bile ( a fluid made by the liver) , 
urine and feces  .
 Heme is found in hemoglobin, a principal component of RBCs 
[Heme: iron + organic compound “porphyrin”]. 
 Heme source in body: 
 80% from hemoglobin
 20% other hemo-protein: cytochrome, myoglobin) 
Hemoglobin degrading and bilirubin 
formation 
Spleen Plasma 
Protein and a.a 
pool
Iron pool
Liver 
globin
iron                       
Heme
Hemoglobin
Bilirubin Binds with 
albumin 
Conjugati
on
process 
Bilirubin Metabolism 
1. Unconjugation process :
 RBCs are phagocytized in the spleen.  Hemoglobin is 
catabolized into amino acids, iron and heme.
 Heme ring is broken open  and converted to unconjugated 
( indirect  ) bilirubin.
 This unconjugated bilirubin is not soluble in water, due to 
intramolecular hydrogen bonding. It is then bound to 
albumin and sent to the liver.
2. Congugation process:
 In liver: Bilirubin is conjugated with Glucouronic acid to 
produce bilirubin diglucuronides, which is water soluble and 
readily transported to bile. and thus out into the small intestine. 
Blilirubin +  Glucouronic acid                bilirubin diglucuronides
 Then conjugated bilirubin is excreted  in bile through bile duct 
to help in food digestion (mainly fat).
UDP-glucuronyl    
transferase
"water soluble" 
"Conjugated BIL""water insoluble" 
Bile

 The excess amount transferred to intestine to be excreted in urine 
and stool. 
 However 95% of the secreted bile is reabsorbed by the small 
intestine. This bile is then resecreted by the liver into the small 
intestine. This process is known as enterohepatic circulation 
 About half of the conjugated bilirubin remaining in the large 
intestine (about 5% of what was originally secreted) is 
metabolised by colonic bacteria to form urobilinogen , which may 
be further oxidized to urobilin and stercobilin . Urobilin, 
stercobilin and their degradation products give feces its brown 
color.
 Elevated levels of bilirubin in blood and urine indicate certain 
diseases.   

 Direct bilirubin: is conjugated (water soluble bilirubin) in 
aqueous solution it reacts rapidly with reagent (direct reacting). 
 Indirect bilirubin: is unconjugated (water insoluble bilirubin) 
because it is less soluble in it reacts more slowly with reagent 
(reaction carried out in methanol). 
- in this case both conjugated and unconjugated bilirubin are 
measured given total bilirubin. Unconjugated will calculated by 
subtracting direct from total and so called indirect. 
 Total bilirubin = D+ ID
• Knowing the level of each type of bilirubin has diagnostic 
important. 
• It is a medical term describes the elevation of bilirubin in 
blood result in yellow color of skin and sclera.(2-2.5mg/dl)
• Other symptoms include nausea, vomiting, dark-colored 
urine , fatigue 
• Types of Jaundice:
• according to the cause of jaundice
it is classified to three main types:
 Pre-hepatic jaundice 
 Hepatic jaundice
 Post-hepatic (most common type)  
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HYPERBILIRUBINEMIA
 Increased plasma concentrations of bilirubin (> 3 mg/dL) occurs 
when  there is an imbalance between its production and excretion 
 Recognized clinically as jaundice
Post-hepatic jaundiceHepatic jaundicePre-hepatic jaundice
 Due to obstruction of 
bile duct which prevents 
passage of bilirubin into
intestine.
 D.Bil will back to liver 
and then to circulation 
elevating its level in 
blood and urine.
 Occur in:
Biliary stricture
Cancer of the pancreas or 
gallbladder
Gallstones
 Due to liver cell damage 
(cancer, cirrhosis or 
hepatitis)
 Conjugation of bilirubin 
decreased (ID.Bil. ). 
 Blilirubin that is conjugated 
is not efficiently secreted 
into bile but leaks to blood 
(D.Bil. ) 
 Occur in :
Cirrhosis (scarring of the    
liver)
Hepatitis
Gilbert's disease
 Due to increase in 
RBCs breakdown due to 
hemolytic anemia.
 The rate of RBCs lysis 
and bilirubin production 
more than ability of 
liver to convert it to the 
conjugated form
 Occur in: 
Erythroblastosis fetalis
Hemolytic anemia
Transfusion reaction
Causes
D.Bil (High)D.Bil, ID.Bil, T.Bil all (High)ID.Bil > D.BilType of Bil.
ALP ( High)ALT, AST (High)
K+ ( High)
Hematology: 
CBC (low Hb) 
Conformationa
l test
haemolytic jaundice hepato-cellular jaundice obstructive jaundice
• High bilirubin levels is common 
• After birth the newborns breaking down the excess RBCs they are born with 
and, because the newborn’s liver is not fully mature, (unable to process the extra 
bilirubin) leads to elevate its level in blood and other body tissues. 
SO, WHAT TYPE OF JUNDUCE IS THIS ???
 Common, particularly in premature infants
 Transient (resolves in the first 10 days)
 Due to immaturity of the liver enzymes 
 Jaundice within the first 24 hrs of life or which takes longer then 10 days
to resolve is usually pathological and needs to be further investigated
 High levels of unconjugated bilirubin are toxic to the newborn – cause a
type of mental retardation known as kernicterus
 New born jaundice treatment:
• Usually newborn is treated by phototherapy which 
breakdown bilirubin (IDD) and convert it to the photo 
isomer form which is more soluble.
Bilirubin Toxicity :
 Very high bilirubin is danger and toxic it may cause 
 brain damage                                   effect on muscles, eyes  
and  Leading to death
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Diagnoses of Jaundice
Hemoglobinopathies
• Decrease, lack of, or abnormal globin
• May be severe hemolytic anemia
• Abnormal Hb with low functionality
• Mutation may be deletion, substitution, 
elongation
• Hb electrophoresis may be helpful
Hb-A Molecule. Hb-A is the major 
adult hemoglobin.
Hemoglobin
• Heme
– Porphyrin ring and Fe
• Globins
– Alpha family on chromosome 16
]--//--[
– Beta family on chromosome 11
]--//--[]—[

Thalassemia
• 1925: Described by Dr. Thomas Cooley and Dr. Pearl Lee 
of Detroit
• 1930’s: Familial pattern recognized
• 1950’s: Alkali denaturation test for Hb F, Hb ELP
• 1960’s: RBC indices
• 1980’s: Histogram, DNA analysis, PCR

How to name thalassemia?
• Named after globin chain that is abnormally 
synthesized !!!!
• Reduced or absent -globin chain : -thalassemia
• Reduced or absent -globin chain : -thalassemia
• Reduced or absent -globin chain : -thalassemia
• Reduced or absent -globin chain : -thalassemia
• Reduced or absent -globin chains 
: -thalassemia
Common  types  of  thalassemia
 -thalassemia
 -thalassemia
ALPHA 
THALASSEMIAS
α Thalassemia
• Absence of α chains will result in increase/ 
excess of  globin chains during fetal life 
and excess β globin chains later in postnatal 
life.
• Severity of disease depends on number of 
genes affected.
Symbolism
Alpha Thalassemia
(/) : Indicates division between genes inherited 
from both parents:
/ (Normal)
• Each chromosome 16 carries 2 genes.  Therefore the total 
complement of  genes in an individual is 4.
Symbolism
Alpha Thalassemia
(-) : Indicates a gene deletion:
-/
- + Thalassemia (one gene deletion)
- 3 functional working genes.
- Called  thal 2. 
Symbolism
Alpha Thalassemia
(-) : Indicates a gene deletion:
--/
- 0 Thalassemia (two gene deletion) in the 
same chromosome.
- 2 functional working genes.
- Called  thal 1. 
Symbolism
Other Thalassemia
• Superscript T denotes nonfunctioning (mutated 
gene, not deletion) gene:
• T
Classification & Terminology
Alpha Thalassemia
• Normal /
• Silent carrier - /
• Minor -/-
--/
• Hb H disease --/-
• Barts hydrops fetalis --/--
α Thalassemia
2 1 2 1
2
2 1
2 1
2 1
2 1
2 1
2 1
Normal Hb
One α gene deletion
α-Thal2
Two α gene deletions
α-Thal1
Three α gene deletions
Hb-H disease
Four α gene deletions
Hydrops fetalis or also called:
Erythroblastosis Fetalis.
α Thalassemia
• As said, the genetic basis of α thal is mostly deletions:  If you have 
4 functional α genes, then you are normal.
• With 3 functional α genes, you are a silent carrier. 
• With 2 functional α genes you have α thalassemia trait which is 
clinically benign, but there is mild microcytic anemia.
• With only one functional α chain, you have severe hemolytic 
anemia with primarily HbH, composed of 4 β chains (β4). This is 
clinically severe.
• In the absence of α chain in the fetus, the gamma forms a tetramer 
of globin chains, and is called Hb Bart’s.
• Both  Hb-H and Hb-Barts are high affinity Hbs, thus neither of them 
is capable of releasing oxygen to the tissues, also these hemoglobins 
are fast moving hemoglobins in Hb electrophoresis at alkaline pH.   
α Thalassemia
• Infants with severe α Thalassemia (zero 
functional alpha genes) and Hb Barts suffer 
from severe intrauterine hypoxia and are 
born with massive generalized fluid 
accumulation, a condition known as hydrops 
fetalis or also called erythroblastosis fetalis.
Thus: in α Thalassemia
• Is usually caused by deletion of 1 or more of the 4 α
globin genes on chromosome 16
• Severity of disease depends on number of the 
deleted α genes.
• Absence of α chains will result in increase/ excess of 
 chains during fetal life and excess β chains later in 
life; Causes hemoglobins like Hb Bart's (4) or HbH 
(β4), to form which are physiologically useless (very 
high affinity).
• Like β thalassemia the excess globin chains causes 
the problem. 
But:
• Alpha chain accumulation and deposition 
are more toxic than beta chain accumulation 
and deposition. Thus beta thalassemia is 
more severe than alpha thalassemia.
α Thalassemia
• Predominant cause of alpha thalassemias is large 
number of gene deletions in the α-globin genes. 
• There are four clinical syndromes present in alpha 
thalassemia: 
♫ Silent Carrier State 
♫Alpha Thalassemia Trait (Alpha Thalassemia Minor) 
♫Hemoglobin H Disease 
♫Bart's Hydrops Fetalis Syndrome 
Silent Carrier α Thalassemia
• -α/αα
• One alpha gene deletion, 3 intact alpha 
genes.
• Healthy persons.
• Normal Hb and Hct
• No treatment
• Can only be detected by DNA studies.
Alpha Thalassemia Trait 
• Also called Alpha Thalassemia Minor. 
• Caused by two missing alpha genes. May be homozygous 
(-α/-α) or heterozygous (--/αα). 
• Exhibits mild microcytic, hypochromic anemia. 
• MCV between 70-75 fL.
• May be confused with iron deficiency anemia. 
• Although some Bart's hemoglobin (4) present at birth, 
but no Bart's hemoglobin present in adults.
Hemoglobin H Disease
• Second most severe form alpha thalassemia. 
• Usually caused by presence of only one intact α
gene producing alpha chains (--/-α).
• Results in accumulation of excess unpaired gamma 
or beta chains.  Born with 10-40% Bart's 
hemoglobin (4). Gradually replaced with 
Hemoglobin H (β4).  In adult, have about 5-40% 
HbH. 
γ4               β4
Hemoglobin H Disease   
• Live normal life; however, infections, pregnancy, 
exposure to oxidative drugs may trigger hemolytic crisis. 
• RBCs are microcytic, hypochromic with marked 
poikilocytosis. Numerous target cells.
• Hb 7-10 g/dl
• Hb electrophoresis: Fast moving band correspondent to 
HbH. 
• HbH vulnerable to oxidation. Gradually precipitate in 
vivo to form Heinz-like bodies of denatured 
hemoglobin. Cells been described has having "golf ball" 
appearance, especially when stained with Brilliant Cresyl 
Blue. 

Hb-H inclusions
Bart’s Hydrops Fetalis Syndrome
• Most severe form. Incompatible with life. Have no functioning 
α chain genes (- -/- -). 
• Baby born with hydrops fetalis, which is edema and ascites 
caused by accumulation serous fluid in fetal tissues as result of 
severe anemia. Also we will see hepatosplenomegaly and 
cardiomegaly. 
• Predominant Hb is Hb Bart, along with Hb Portland and traces 
of HbH. 
• Hb Bart's has high oxygen affinity so cannot carry oxygen to 
tissues. Fetus dies in utero or shortly after birth. At birth, you 
will see severe hypochromic, microcytic anemia with numerous 
NRBCs. 
Hydrops Fetalis
The blood film of neonate with hemoglobin Bart’s hydrops fetalis 
showing anisocytosis, poikilocytosis and numerous nucleated red 
blood cells (NRBC).
State Genotype Genes Features
Normal / 4 normal
Hetero +
-thal-2
/ –  3 Essentially normal
Hetero °
-thal-1
/ – – 2 Micro / Hypo
Mild Anemia
Bart’s 2-8% (at birth)
Hb H <2%
Homo +
-thal-1
– / –  2
+ + °
Hb-H 
Disease
– / – – 1 Moderate Micro/Hypo 
anemia: Barts <10%, Hb 
H <40%
homo °
Hydrops
– – / – – 0 Hb A 0%, Bart’s 70-80%
Portland 10-20%
Comparison of α Thalassemias
Phenotype Hb A Hb Barts Hb H
Normal 97-98% 0 0
Silent Carrier 96-98% 0-2%
(At birth)
0
α Thalassemia Trait 85-95% 2-8%
(At birth)
<2%
Hb H Disease Dec <10%
(At birth)
5-40%
Hydrops Fetalis 0 70-80% (with 20% 
Hb Portland)
0-20%
α Thalassemia Syndromes
. They are the most important types of thalassemias because they are 
so common and usually produce severe anemia in their 
homozygous and compound heterozygous states (compound= 
when combined with other hemoglobinopathies or thalassemias)
• β thalassemias are autosomal inherited disorders of β globin
synthesis. In most, globin structure is normal but the rate of 
production is reduced because of decrease in transcription of DNA, 
abnormal processing of pre-mRNA, or decreased translation of 
mRNA  leading to decreased Hb-A production (A=Adult).
β Thalassemia
β Thalassemia
• Usually and mostly they are caused by gene mutations in the 
gene in chromosome# 11, although deletions do occur.
• Hundreds of mutations possible in the  globin gene, therefore 
thalassemia is more diverse disease in its presentation (the 
presentation differs between people depending on the type of 
mutation).
• This results in excess alpha chains, because they cannot find 
their counterparts (the beta chains) to bind to.
Type of mutations that could occur
Immature mRNA transcript
5’ 3’
Gene (DNA)
Transcription
Translation
ProteinNH2 COOH
exon1 intron1 exon2 intron2 exon3 (AAA) signal
Promoter/Enhancer
5’ exon1 exon2 exon3 AAAA…AAA  3’
Mature mRNA transcript
ATG
“start”
“stop” 
codon
Processing
5’ 3’exon1 exon2 exon3 AAAA…AAA
X X
X X
X
X
Again:
• β thalassemias are usually and mostly due 
to single base pair substitutions rather than 
deletions. Although deletions do occur.
Beta  (ß) thalassemia
It appears when a person does not produce 
enough beta chains for hemoglobin. 
It is mainly prevalent in the Mediterranean 
region countries , such as  Greece, Cyprus, 
Italy, Palestine and Lebanon.
ß thalassemia and malaria
•Thalassemic RBCs offers protection 
against severe malaria caused by 
Plasmodium falciparum.
•The effect is associated with reduced 
parasite multiplication within RBCs.
•Among the contributing factors may be 
the variable persistence of hemoglobin F, 
which is  relatively resistant to digestion 
by malarial hemoglobinases.
In brief:
• The anemia is due to two main components:
– Ineffective erythropoiesis (intramedullary).
– Extravascular Hemolysis in RES esp. spleen
• A third component that could contribute for the severity 
of anemia is Splenomegaly that may also worsen the 
anemia, because of two components: the (1) increased 
sequestration, and (2) increased plasma volume caused 
by the splenomegaly (dilutional).
There is also:
• Extramedullary erythropoiesis occurs, which also 
contributes for the splenomegaly, it is worthy to 
note that extramedullary erythropoiesis is not a 
perfect process, this is why in thalassemias we 
may see tear drop RBCs, and nucleated RBCs 
(NRBCs). Although, the NRBC seen in the blood 
film are from both the BM and the extramedullary 
erythropoiesis.
The pathophysiology of β-thalassaemia
At what age could β Thalassemia cause 
its effect???
• In contrast to α globin, β globin is not necessary 
during fetal life (Hb-F= α2γ2), thus the onset of 
β Thalassemia isn’t apparent until a few months 
after birth, when HbF is switched to HbA. 
Types of βThalassemia
Three common types of  Thalassemia:
 ++ Thalassemia: The production of  chain is mildly reduced.
 + Thalassemia: The production of  chain is more reduced than 
++ But NOT ABSENT. ++ and + are caused by mutation in 
Promoter region, 5`UTR, Cap site, Consensus sites, within Introns, 
3`UTR, or Poly A site, and change in coding region.
 0 Thalassemia: ABSENCE of  chain production. It is caused by 
mutation in Initiation codon, Splicing at junctions, Frameshift, 
Nonsense mutation.
In + and ++ thalassemias, the mutated gene encodes for a small 
amounts of normal  mRNA. The quantity of  globin chain, which are 
made, varies largely from one molecular mutation/defect to another.
Excess α chains will precipitate in the RBC precursor cells and causes 
the ineffective erythropoiesis, also if it escape intramedullary 
ineffective erythropoiesis, RBCs possessing precipitated α chains will 
be hemolyzed in the P.B. by the RES (esp. in spleen).
0 Thalassemia
The β gene is unable to encode for any functional mRNA and 
therefore there is no  chain synthesis. So the situation will be 
more difficult than + thalassemia.
More excess α chains will precipitate in RBC precursor cells and 
causes the ineffective erythropoiesis, also if it escape ineffective 
erythropoiesis, red cell possessing precipitated alpha chains will 
be hemolyzed in the P.B. by the RES (esp. in the spleen).
Again: What is Thalassemia?
• A group of inherited single gene disorders resulting in 
reduced or no production of one or more globin chains
• This results in an imbalance of globin chain production, 
with the normal excess chain producing the pathological 
effects: 
♪ Damage to RBC precursors →ineffective red cell production in 
BM. 
♪ Damage to mature red cells → hemolytic anemia
• Resulting in hypochromic, microcytic anemia 
Each one of us inherit one gene from 
each parent
β Gene
β Gene
β Gene
β Gene
β Gene
β Gene
Homozygous: 
Normal Both gene 
are normal
Heterozygous: one 
normal and one 
abnormal/mutated
Homozygous: Abnormal 
Both gene are 
abnormal/mutated
X
XX
Who is at risk?
Ethnic origin is very critical!
Classical Clinical Syndromes of  Thalassemia; 
thalassemia can be presented as:
o Silent carrier state – mildest form of  thal. 
  thalassemia minor - heterozygous disorder resulting 
in mild hypochromic, microcytic hemolytic anemia. 
  thalassemia intermedia - Severity lies between the 
minor and major. 
  thalassemia major - homozygous disorder resulting in 
severe life long transfusion-dependent hemolytic 
anemia. 
Silent Carrier State for β Thalassemia
• Are various heterozygous (from one parent) β
gene mutations that produce only small decrease 
in production of β globin chains. 
• Patients have nearly normal alpha/beta chain ratio 
and no hematologic abnormalities. 
• Have normal levels of HbA2. 
β Thalassemia Minor (Trait)
• Caused by heterozygous (from one parent) mutations that 
affect β globin synthesis.
• β Chains production and thus Hb-A production is more 
reduced than the silent carrier Hb-A.
• Usually presents as mild, asymptomatic hemolytic 
anemia unless patient in under stress such as pregnancy, 
infection, or folic acid deficiency. 
• Have one normal β gene and one mutated β gene. 
• Hemoglobin level in 10-13 g/dL range with normal or 
slightly elevated RBC count (RCC). 
β Thalassemia Minor (Trait)  
• Anemia usually hypochromic and microcytic with slight aniso 
and poik, including target cells and elliptocytes; also may see 
basophilic stippling. 
• Rarely see hepatomegaly or splenomegaly. 
• Have high HbA2 levels (3.6-8.0%) and normal to slightly 
elevated HbF levels. 
• Normally require no treatment.
β Thalassemia Minor (Trait)
• 2- 6% HbF (N = < 1% after age 1 year)
• 3.6 - 8% HbA2 (N = 2.2-3.6%)
• 87 - 95% HbA (N=95-100%)
β Thalassemia Intermedia 
• Patients able to maintain minimum Hb (7 g/dL or 
greater) without transfusion dependence.
• Expression of disorder falls between thalassemia 
minor and thalassemia major.
• We will see increase in both HbA2 production and 
HbF production. 
• Peripheral blood smear picture is similar to 
thalassemia minor. 
β Thalassemia Intermedia  
• Have varying symptoms of anemia, jaundice, 
splenomegaly and hepatomegaly. 
• Have significant increase in bilirubin levels.
• Anemia usually becomes worse with infections, 
pregnancy, or folic acid deficiency. 
• May become transfusion dependent. 
• Tend to develop iron overloads as result of 
increased gastrointestinal absorption. 
• Usually survive into adulthood.
β Thalassemia Major
• Characterized by very severe microcytic, 
hypochromic anemia.
• Detected early in childhood: 
• Hb level lies between 2 and 8 g/dL. 
• Severe anemia causes marked bone changes due to 
expansion of marrow space for increased 
erythropoiesis (Epo is increased).
• See characteristic changes in skull, long bones, and 
hand bones.
β Thalassemia Major
• Have protrusion upper teeth and Mongoloid facial features.
• Physical growth and development delayed. 
• Peripheral blood shows markedly hypochromic, microcytic 
erythrocytes with extreme poikilocytosis, such as target cells, and 
elliptocytes. See marked basophilic stippling and numerous 
NRBCs.
• MCV in range of 50 to 60 fl.
• Retic count seen (2-8%). 
• Most of Hemoglobin present is Hb F with slight increase in 
HbA2. 
β Thalassemia Major
• Regular transfusions usually begin around one year of age and 
continue throughout life.
• Excessive number of transfusions results in transfusional 
hemosiderosis;  Without iron chelation, patient develops cardiac 
disease, liver cirrhosis, and endocrine deficiencies. 
• Dangers in continuous transfusion therapy: 
– Development of iron overload. 
– Development of alloimmunization (developing antibodies to transfused 
RBCs). 
– Risk of transfusion-transmitted diseases (e.g. hepatitis, AIDS). 
• Bone marrow transplants may be future treatment, along with 
genetic engineering and new drug therapies. 
β Thalassemia Major
Anisopoikilocytosis, NRBC, microcytosis, hypochromia
Cooley’s Anemia
• This is another name for β Thalassemia 
Major, because Cooley was the first one to 
describe these cases.
Thalassemic face
β Thalassemia Major
Hepatosplenomegaly
Hair on End Appearance
Dark skin due to iron overload
Thalassaemia major-life expectancy
• Without regular transfusion
– Less than 10 years
• With regular transfusion and no or poor iron 
chelation
– Less than 25 years
• With regular transfusion and good iron 
chelation
– 40 years, or longer??
Good iron chelation using desferoxamine (iron chelator) 
prolongs the life expectancy of Cooley’s anemic patients, 
otherwise cardiac failure, liver cirrhosis, and endocrine 
deficiencies could occur and causing death. 
Comparison of β Thalassemias
GENOTYPE Hb A Hb A2 Hb F
NORMAL Normal Normal Normal
SILENT CARRIER Normal Normal Normal
β THAL MINOR Dec N to Inc N to Inc
β THAL INTERMEDIA Dec N to Inc Increased
β THAL MAJOR Dec Usually Inc Increased
δβ Thalassemia
• In some cases:
• They result from deletions of the δ and β
globin genes.
• Homozygotes have 100% Hb-F, with 
moderate anemia 8-10 g/dl. With 
microcytosis and hypochromia.
• Heterozygotes have 15-25% Hb-F. 
δβ Thalassemia
• They appear to have unequal crossing over 
between the δ and β globin gene loci with the 
production of δβ fused gene which codes for δβ
fused globin chains that when combine to α
chains forms an abnormal hemoglobin called Hb 
Lepore, which have an electrophoretic mobility 
like sickle hemoglobin. 
δβ Thalassemia: Classification
• Because there are two causes for delta beta 
thalassemia: deletions and fusion. Delta Beta 
thalassemias can be classified into:
– (δβ0) thalassemia: caused by complete deletion of δβ
genes. Homozygotes characterized by 100% HbF. With 
moderate anemia 8-10 g/dl.
– (δβ+) thalassemia: or called Hb Lepore thalassemia. 
Homozygotes have only HbF and Hb Lepore. 

Hemoglobinopathies
• Production of abnormal globin chains.
• Abnormal hemoglobins are the synthesised : 
structural variants.
• Abnormal hemoglobin has different 
property from its counterpart.
• Rate of synthesis of abnormal globin chain 
is reduced, resembling mild form of 
thalassemia
Structural   Variants
(469 var submitted, July 2002)
• Hb Anantharaj
cd11(Lys-Glu)
• Hb Mahidol
cd74(Asp-His)
• Hb Siam
cd15(Gly-Arg)
• Hb Suan Dok
cd109(Leu-Arg)
• Hb Constant  
spring
cd142(stop-Gln)
Hb  Constant  Spring
• Point  mutation  at  termination          
codon
• UAA-->CAA
• 31  amino  acids  extension  
• Total  amino  acid  = 172
• Phenotype  similar  to  +-thalassemia
-Structural  Variants
(649 var submitted, July 2002)
• Hb  D-Punjab
cd121(Glu-Gln)
• Hb J-Bangkok
cd56(Gly-Asp)
• Hb  S
cd6(Glu-Val)
• Hb G-Siriraj
cd7(Glu-Lys)
• Hb  Tak
cd147(+AC)
• Hb  E
cd26(Glu-Lys)
Hemoglobin   E
• Commonly   found   in  Thais
• Result  of  point  mutation  at  
codon 26  of  b-globin gene.
• Glutamic acid-->Lysine
• Phenotype  similar to β +-thalassemia
Hemoglobin  S
• Commonly  found  among the black.
• Cause  of  sickle  cell  anemia.
• Result  of  point  mutation  at  codon 6  of 
β -globin gene; Glutamic acid-->Valine
• Hb S  can  perform  polymerization, esp. 
when deoxygenated.
Order  of  Severity
• Hb Bart’s   hydrops   fetalis.   
• β-thalassemia  major.
• β-thalassemia/Hb E  disease.
• Hb H disease.
Clinical  Symptoms
• Anemia, Jaundice.
• Hepatosplenomegaly.
• Bone  change-->mongoloid  face.
• Iron  overload-->growth  retardation, 
heart  failure, DM, dark-colored  skin , 
etc.
Management
• Blood  transfusion
• Iron  chelation: Desferroxamine, 
• Splenectomy
• Stem cell transplantation : BM or 
Cord blood
• Prenatal   diagnosis (PND)
• Supportive: Folic  acid
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